Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Several stocks are experiencing significant pre-market trading movements. AgileThought, Inc. (AGIL), Digital Brands Group, Inc. (DBGI), NanoVibronix, Inc. (NAOV), Tingo Group, Inc. (TIO), Top KingWin Ltd. (TCJH), Aravive, Inc. (ARAV), 1847 Holdings LLC (EFSH), Dermata Therapeutics, Inc. (DRMA), Arcadia Biosciences, Inc. (RKDA), and Globalstar, Inc. (GSAT) are among the gainers. Outlook Therapeutics, Inc. (OTLK), FibroGen, Inc. (FGEN), MasterCraft Boat Holdings, Inc. (MCFT), Ambarella, Inc. (AMBA), Genius Group Limited (GNS), TD Holdings, Inc. (GLG), Tivic Health Systems, Inc. (TIVC), VAALCO Energy, Inc. (EGY), LENSAR, Inc. (LNSR), and OKYO Pharma Limited (OKYO) are among the losers.
August 30, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AgileThought, Inc. rose 96.5% in pre-market trading after falling 17% on Tuesday.
The stock is rising in pre-market trading, indicating a potential recovery from the previous day's fall.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Digital Brands Group, Inc. shares gained 57.9% in pre-market trading after a 1-for-25 reverse stock split.
The stock is rising in pre-market trading following a reverse stock split, which often leads to a temporary increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
NanoVibronix, Inc. shares climbed 49% in pre-market trading after the company reported positive outcomes from a UroShield study.
The stock is rising in pre-market trading following positive study outcomes, which could increase investor confidence in the company's products.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
FibroGen, Inc. shares fell 24.2% in pre-market trading after the company reported topline results from a Phase 3 clinical study.
The stock is falling in pre-market trading following the release of Phase 3 clinical study results, which may have disappointed investors.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
Outlook Therapeutics, Inc. fell 78.4% in pre-market trading after the company received an FDA complete response letter regarding ONS-5010.
The stock is falling in pre-market trading following a negative response from the FDA, which could impact the company's future revenue and profitability.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100